Alnylam Pharmaceuticals, Inc. (ALNY): Eastern Capital Owns 3.8 Million Shares

Page 1 of 8

Given the volatile nature of the markets, investors should pay attention to the latest moves made by elite hedge funds and other investors in their conviction picks, to get a better idea of the companies and sectors that they are confident in and those in which they may be losing faith. With that mind, we have embedded one of the newest 13G filings below and on the following pages, submitted to the SEC by Eastern Capital. The filing reveals a 3.80 million-share position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), accounting for 4.5% of the company’s stock.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
EASTERN CAPITAL LIMITED 0 3,802,341 0 3,802,341 3,802,341 4.5%
PORTFOLIO SERVICES LTD 0 3,802,341 0 3,802,341 3,802,341 4.5%
KENNETH B. DART 0 3,802,341 0 3,802,341 3,802,341 4.5%

Page 1 of 8 SEC Filing

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange
Act of 1934
(Amendment No. 4)*

Alnylam Pharmaceuticals, Inc.

(Name of Issuer)

COMMON STOCK, $0.01
PAR VALUE PER SHARE

(Title of Class of Securities)

02043Q107

(CUSIP Number)

William Sullivan,
10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

February 25, 2016

(Date
of Event which Requires Filing of this Statement
)

Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨  Rule
13d-1(b)

  Rule
13d-1(c)

¨  Rule 13d-1(d)

* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover
page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)

Page 1 of 8